About 20 percent of all individuals with hemophilia A begin to produce antibodies in their blood against the specific factor protein; the presence of antibodies may then rapidly destroy infused factor VIII.
Hemophilia A is diagnosed with laboratory tests that can detect the presence of clotting factor VIII, factor IX, and others, as well as the presence or absence of clotting factor inhibitors.
Gene carriers for both forms of hemophilia can be detected through DNA studies in conjunction with results from factor VIII assays.
Comprehensive care addresses children's needs by providing various types of counseling to help deal with the psychosocial aspects of diseases such as von Willebrand's and hemophilia.
With mild bleeding episodes in persons afflicted with hemophilia A, infusions of a drug called desmopressin (DDAVP) may be administered.
